Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 62

1.

Treatment-Specific Composition of the Gut Microbiota Is Associated With Disease Remission in a Pediatric Crohn's Disease Cohort.

Sprockett D, Fischer N, Boneh RS, Turner D, Kierkus J, Sladek M, Escher JC, Wine E, Yerushalmi B, Dias JA, Shaoul R, Kori M, Snapper SB, Holmes S, Bousvaros A, Levine A, Relman DA.

Inflamm Bowel Dis. 2019 Nov 14;25(12):1927-1938. doi: 10.1093/ibd/izz130.

PMID:
31276165
2.

Crohn's Disease Exclusion Diet Plus Partial Enteral Nutrition Induces Sustained Remission in a Randomized Controlled Trial.

Levine A, Wine E, Assa A, Sigall Boneh R, Shaoul R, Kori M, Cohen S, Peleg S, Shamaly H, On A, Millman P, Abramas L, Ziv-Baran T, Grant S, Abitbol G, Dunn KA, Bielawski JP, Van Limbergen J.

Gastroenterology. 2019 Aug;157(2):440-450.e8. doi: 10.1053/j.gastro.2019.04.021. Epub 2019 Jun 4.

PMID:
31170412
3.

Novel Genomic Biomarker Candidates for Cervical Cancer As Identified by Differential Co-Expression Network Analysis.

Kori M, Gov E, Arga KY.

OMICS. 2019 May;23(5):261-273. doi: 10.1089/omi.2019.0025. Epub 2019 Apr 30.

PMID:
31038390
4.

Pediatric Eosinophilic Esophagitis: Results of the European Retrospective Pediatric Eosinophilic Esophagitis Registry (RetroPEER).

Hoofien A, Dias JA, Malamisura M, Rea F, Chong S, Oudshoorn J, Nijenhuis-Hendriks D, Otte S, Papadopoulou A, Romano C, Gottrand F, Miravet VV, Orel R, Oliva S, Junquera CG, Załęski A, Urbonas V, Garcia-Puig R, Gomez MJM, Dominguez-Ortega G, Auth MK, Kori M, Ben Tov A, Kalach N, Velde SV, Furman M, Miele E, Marderfeld L, Roma E, Zevit N.

J Pediatr Gastroenterol Nutr. 2019 Apr;68(4):552-558. doi: 10.1097/MPG.0000000000002215.

PMID:
30540712
5.

Helicobacter pylori and some aspects of gut microbiota in children.

Kori M, Daugule I, Urbonas V.

Helicobacter. 2018 Sep;23 Suppl 1:e12524. doi: 10.1111/hel.12524. Review.

PMID:
30203591
6.

Potential biomarkers and therapeutic targets in cervical cancer: Insights from the meta-analysis of transcriptomics data within network biomedicine perspective.

Kori M, Yalcin Arga K.

PLoS One. 2018 Jul 18;13(7):e0200717. doi: 10.1371/journal.pone.0200717. eCollection 2018.

7.

Intestinal granulomatous disease: what is the first call.

Guri A, Kori M, Herskovitz P, Zimhony O.

BMJ Case Rep. 2018 Apr 19;2018. pii: bcr-2017-223094. doi: 10.1136/bcr-2017-223094.

PMID:
29674398
8.

Design and synthesis of 1-(1-benzothiophen-7-yl)-1H-pyrazole, a novel series of G protein-coupled receptor 52 (GPR52) agonists.

Nakahata T, Tokumaru K, Ito Y, Ishii N, Setoh M, Shimizu Y, Harasawa T, Aoyama K, Hamada T, Kori M, Aso K.

Bioorg Med Chem. 2018 May 1;26(8):1598-1608. doi: 10.1016/j.bmc.2018.02.005. Epub 2018 Feb 10.

PMID:
29478803
9.

Azithromycin and metronidazole versus metronidazole-based therapy for the induction of remission in mild to moderate paediatric Crohn's disease : a randomised controlled trial.

Levine A, Kori M, Kierkus J, Sigall Boneh R, Sladek M, Escher JC, Wine E, Yerushalmi B, Amil Dias J, Shaoul R, Veereman Wauters G, Boaz M, Abitbol G, Bousvaros A, Turner D.

Gut. 2019 Feb;68(2):239-247. doi: 10.1136/gutjnl-2017-315199. Epub 2018 Feb 2.

PMID:
29420227
10.

Primary and Secondary Antibiotic Resistance of Helicobacter pylori in Israeli Children and Adolescents.

Kori M, Yahav J, Berdinstein R, Shmuely H.

Isr Med Assoc J. 2017 Dec;19(12):747-750.

11.

Multiomics Analysis of Tumor Microenvironment Reveals Gata2 and miRNA-124-3p as Potential Novel Biomarkers in Ovarian Cancer.

Gov E, Kori M, Arga KY.

OMICS. 2017 Oct;21(10):603-615. doi: 10.1089/omi.2017.0115. Epub 2017 Sep 22.

PMID:
28937943
12.

Finely controlled multimetallic nanocluster catalysts for solvent-free aerobic oxidation of hydrocarbons.

Takahashi M, Koizumi H, Chun WJ, Kori M, Imaoka T, Yamamoto K.

Sci Adv. 2017 Jul 26;3(7):e1700101. doi: 10.1126/sciadv.1700101. eCollection 2017 Jul.

13.

RNA-based ovarian cancer research from 'a gene to systems biomedicine' perspective.

Gov E, Kori M, Arga KY.

Syst Biol Reprod Med. 2017 Aug;63(4):219-238. doi: 10.1080/19396368.2017.1330368. Epub 2017 Jun 2. Review.

PMID:
28574782
14.

Joint ESPGHAN/NASPGHAN Guidelines for the Management of Helicobacter pylori in Children and Adolescents (Update 2016).

Jones NL, Koletzko S, Goodman K, Bontems P, Cadranel S, Casswall T, Czinn S, Gold BD, Guarner J, Elitsur Y, Homan M, Kalach N, Kori M, Madrazo A, Megraud F, Papadopoulou A, Rowland M; ESPGHAN, NASPGHAN.

J Pediatr Gastroenterol Nutr. 2017 Jun;64(6):991-1003. doi: 10.1097/MPG.0000000000001594.

PMID:
28541262
15.

Once- Versus Twice-daily Mesalazine to Induce Remission in Paediatric Ulcerative Colitis: A Randomised Controlled Trial.

Turner D, Yerushalmi B, Kori M, Broide E, Mozer-Glassberg Y, Shaoul R, Kolho KL, Shteyer E, Shamaly H, Ledder O, Cohen S, Peleg S, On A, Levine A.

J Crohns Colitis. 2017 May 1;11(5):527-533. doi: 10.1093/ecco-jcc/jjw180.

PMID:
28453754
16.

Mesalamine Enemas for Induction of Remission in Oral Mesalamine-refractory Pediatric Ulcerative Colitis: A Prospective Cohort Study.

Levine A, Yerushalmi B, Kori M, Broide E, Mozer-Glassberg Y, Shaoul R, Kolho KL, Shteyer E, Shamaly H, Ledder O, Cohen S, Peleg S, Shabat CS, Focht G, Shachmon E, Boaz M, On A, Turner D.

J Crohns Colitis. 2017 Aug 1;11(8):970-974. doi: 10.1093/ecco-jcc/jjx042.

PMID:
28369299
17.

Discovery of Novel, Highly Potent, and Selective Matrix Metalloproteinase (MMP)-13 Inhibitors with a 1,2,4-Triazol-3-yl Moiety as a Zinc Binding Group Using a Structure-Based Design Approach.

Nara H, Kaieda A, Sato K, Naito T, Mototani H, Oki H, Yamamoto Y, Kuno H, Santou T, Kanzaki N, Terauchi J, Uchikawa O, Kori M.

J Med Chem. 2017 Jan 26;60(2):608-626. doi: 10.1021/acs.jmedchem.6b01007. Epub 2017 Jan 9.

PMID:
27966948
18.
19.

Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors.

Nara H, Sato K, Kaieda A, Oki H, Kuno H, Santou T, Kanzaki N, Terauchi J, Uchikawa O, Kori M.

Bioorg Med Chem. 2016 Dec 1;24(23):6149-6165. doi: 10.1016/j.bmc.2016.09.009. Epub 2016 Sep 14.

PMID:
27825552
20.

Discovery of a 7-arylaminobenzimidazole series as novel CRF1 receptor antagonists.

Mochizuki M, Kori M, Kono M, Yano T, Sako Y, Tanaka M, Kanzaki N, Gyorkos AC, Corrette CP, Aso K.

Bioorg Med Chem. 2016 Oct 1;24(19):4675-4691. doi: 10.1016/j.bmc.2016.08.005. Epub 2016 Aug 4.

PMID:
27567079
21.

Molecular signatures of ovarian diseases: Insights from network medicine perspective.

Kori M, Gov E, Arga KY.

Syst Biol Reprod Med. 2016 Aug;62(4):266-82. doi: 10.1080/19396368.2016.1197982. Epub 2016 Jun 24.

PMID:
27341345
22.

Design and Synthesis of Benzimidazoles As Novel Corticotropin-Releasing Factor 1 Receptor Antagonists.

Mochizuki M, Kori M, Kobayashi K, Yano T, Sako Y, Tanaka M, Kanzaki N, Gyorkos AC, Corrette CP, Cho SY, Pratt SA, Aso K.

J Med Chem. 2016 Mar 24;59(6):2551-66. doi: 10.1021/acs.jmedchem.5b01715. Epub 2016 Mar 7.

PMID:
26901666
23.

Homozygous deletion of TRMT10A as part of a contiguous gene deletion in a syndrome of failure to thrive, delayed puberty, intellectual disability and diabetes mellitus.

Zung A, Kori M, Burundukov E, Ben-Yosef T, Tatoor Y, Granot E.

Am J Med Genet A. 2015 Dec;167A(12):3167-73. doi: 10.1002/ajmg.a.37341. Epub 2015 Aug 22.

PMID:
26297882
24.

Inflammatory bowel disease: an emergent disease among Ethiopian Jews migrating to Israel.

Bar-Gil Shitrit A, Koslowsky B, Kori M, Paz K, Adar T, Israeli E, Ben-Horin S, Berdichevski T, Coscas D, Gal E, Odes S, Shaul R, Ben-Ya'acov A, Goldin E.

Inflamm Bowel Dis. 2015 Mar;21(3):631-5. doi: 10.1097/MIB.0000000000000311.

PMID:
25581835
25.

Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach.

Nara H, Sato K, Naito T, Mototani H, Oki H, Yamamoto Y, Kuno H, Santou T, Kanzaki N, Terauchi J, Uchikawa O, Kori M.

J Med Chem. 2014 Nov 13;57(21):8886-902. doi: 10.1021/jm500981k. Epub 2014 Oct 15.

PMID:
25264600
26.

Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1″ binding site.

Nara H, Sato K, Naito T, Mototani H, Oki H, Yamamoto Y, Kuno H, Santou T, Kanzaki N, Terauchi J, Uchikawa O, Kori M.

Bioorg Med Chem. 2014 Oct 1;22(19):5487-505. doi: 10.1016/j.bmc.2014.07.025. Epub 2014 Aug 7.

PMID:
25192810
27.

Anti-diarrhoeal investigation from aqueous extract of Cuminum cyminum Linn. Seed in Albino rats.

Sahoo HB, Sahoo SK, Sarangi SP, Sagar R, Kori ML.

Pharmacognosy Res. 2014 Jul;6(3):204-9. doi: 10.4103/0974-8490.132596.

28.

Discovery of the first potent and orally available agonist of the orphan G-protein-coupled receptor 52.

Setoh M, Ishii N, Kono M, Miyanohana Y, Shiraishi E, Harasawa T, Ota H, Odani T, Kanzaki N, Aoyama K, Hamada T, Kori M.

J Med Chem. 2014 Jun 26;57(12):5226-37. doi: 10.1021/jm5002919. Epub 2014 Jun 12.

PMID:
24884590
29.

Design, synthesis, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase inhibitors.

Kono M, Matsumoto T, Imaeda T, Kawamura T, Fujimoto S, Kosugi Y, Odani T, Shimizu Y, Matsui H, Shimojo M, Kori M.

Bioorg Med Chem. 2014 Feb 15;22(4):1468-78. doi: 10.1016/j.bmc.2013.12.023. Epub 2013 Dec 20.

PMID:
24440478
30.

Pegylated interferon alfa and ribavirin for children with chronic hepatitis C.

Rosen I, Kori M, Eshach Adiv O, Yerushalmi B, Zion N, Shaoul R.

World J Gastroenterol. 2013 Feb 21;19(7):1098-103. doi: 10.3748/wjg.v19.i7.1098.

31.

Synthesis, SAR study, and biological evaluation of a series of piperazine ureas as fatty acid amide hydrolase (FAAH) inhibitors.

Kono M, Matsumoto T, Kawamura T, Nishimura A, Kiyota Y, Oki H, Miyazaki J, Igaki S, Behnke CA, Shimojo M, Kori M.

Bioorg Med Chem. 2013 Jan 1;21(1):28-41. doi: 10.1016/j.bmc.2012.11.006. Epub 2012 Nov 15.

PMID:
23218778
32.

Lack of association between seroconversion and catch-up growth in children with celiac disease.

Zung A, Kori M.

J Pediatr Endocrinol Metab. 2012;25(1-2):131-7.

PMID:
22570962
33.

A novel glycogen synthase kinase-3 inhibitor 2-methyl-5-(3-{4-[(S )-methylsulfinyl]phenyl}-1-benzofuran-5-yl)-1,3,4-oxadiazole decreases tau phosphorylation and ameliorates cognitive deficits in a transgenic model of Alzheimer's disease.

Onishi T, Iwashita H, Uno Y, Kunitomo J, Saitoh M, Kimura E, Fujita H, Uchiyama N, Kori M, Takizawa M.

J Neurochem. 2011 Dec;119(6):1330-40. doi: 10.1111/j.1471-4159.2011.07532.x. Epub 2011 Nov 2.

34.

Enantioselective synthesis of the novel chiral sulfoxide derivative as a glycogen synthase kinase 3beta inhibitor.

Saitoh M, Kunitomo J, Kimura E, Yamano T, Itoh F, Kori M.

Chem Pharm Bull (Tokyo). 2010 Sep;58(9):1252-4.

35.

Evidence-based recommendations for bowel cleansing before colonoscopy in children: a report from a national working group.

Turner D, Levine A, Weiss B, Hirsh A, Shamir R, Shaoul R; Israeli Society of Pediatric Gastroenterology and Nutrition (ISPGAN), Berkowitz D, Bujanover Y, Cohen S, Eshach-Adiv O, Jamal G, Kori M, Lerner A, On A, Rachman L, Rosenbach Y, Shamaly H, Shteyer E, Silbermintz A, Yerushalmi B.

Endoscopy. 2010 Dec;42(12):1063-70. doi: 10.1055/s-0030-1255646. Epub 2010 Jul 28. Review.

PMID:
20669091
36.

Adrenal cortisol secretion capacity in children and adolescents with new-onset, mild Crohn's disease.

Zung A, Kori M, Dinary G, Broide E, Yerushalmi B, Levine A.

J Pediatr. 2010 Feb;156(2):296-301. doi: 10.1016/j.jpeds.2009.08.046. Epub 2009 Oct 27.

PMID:
19863968
37.

2-{3-[4-(Alkylsulfinyl)phenyl]-1-benzofuran-5-yl}-5-methyl-1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3beta with good brain permeability.

Saitoh M, Kunitomo J, Kimura E, Iwashita H, Uno Y, Onishi T, Uchiyama N, Kawamoto T, Tanaka T, Mol CD, Dougan DR, Textor GP, Snell GP, Takizawa M, Itoh F, Kori M.

J Med Chem. 2009 Oct 22;52(20):6270-86. doi: 10.1021/jm900647e.

PMID:
19775160
38.

Efficacy of a novel, orally active GSK-3 inhibitor 6-Methyl-N-[3-[[3-(1-methylethoxy)propyl]carbamoyl]-1H-pyrazol-4-yl]pyridine-3-carboxamide in tau transgenic mice.

Uno Y, Iwashita H, Tsukamoto T, Uchiyama N, Kawamoto T, Kori M, Nakanishi A.

Brain Res. 2009 Nov 3;1296:148-63. doi: 10.1016/j.brainres.2009.08.034. Epub 2009 Aug 19.

PMID:
19698704
39.

Comparison of two dosing methods for induction of response and remission with oral budesonide in active pediatric Crohn's disease: a randomized placebo-controlled trial.

Levine A, Kori M, Dinari G, Broide E, Shaoul R, Yerushalmi B, On A, Bujanover Y, Pröls M, Greinwald R; Israeli Pediatric Budesonide Study Group.

Inflamm Bowel Dis. 2009 Jul;15(7):1055-61. doi: 10.1002/ibd.20881.

PMID:
19229988
40.

Total synthesis of rapamycin.

Ley SV, Tackett MN, Maddess ML, Anderson JC, Brennan PE, Cappi MW, Heer JP, Helgen C, Kori M, Kouklovsky C, Marsden SP, Norman J, Osborn DP, Palomero MA, Pavey JB, Pinel C, Robinson LA, Schnaubelt J, Scott JS, Spilling CD, Watanabe H, Wesson KE, Willis MC.

Chemistry. 2009;15(12):2874-914. doi: 10.1002/chem.200801656.

PMID:
19204960
41.

Helicobacter pylori infection in young children detected by a monoclonal stool antigen immunoassay.

Kori M, Goldstein E, Granot E.

Pediatr Infect Dis J. 2009 Feb;28(2):157-9. doi: 10.1097/INF.0b013e318185a74f.

PMID:
19106773
42.

Collagenous gastritis: a rare cause of abdominal pain and iron-deficiency anemia.

Kori M, Cohen S, Levine A, Givony S, Sokolovskaia-Ziv N, Melzer E, Granot E.

J Pediatr Gastroenterol Nutr. 2007 Nov;45(5):603-6. No abstract available.

PMID:
18030241
43.

Look-back study of Hepatitis C in teenagers after blood transfusions as neonates.

Kori M, Flidel-Rimon O, Sigler E, Shinwell E, Granot E.

Acta Paediatr. 2007 Jul;96(7):1050-2. Epub 2007 May 10.

PMID:
17498189
44.

Evaluation of proximal tooth contact tightness at rest and during clenching.

Oh SH, Nakano M, Bando E, Shigemoto S, Kori M.

J Oral Rehabil. 2004 Jun;31(6):538-45.

PMID:
15189310
45.

Diclofenac inhibits proliferation and differentiation of neural stem cells.

Kudo C, Kori M, Matsuzaki K, Yamai K, Nakajima A, Shibuya A, Niwa H, Kamisaki Y, Wada K.

Biochem Pharmacol. 2003 Jul 15;66(2):289-95.

PMID:
12826271
46.

The significance of routine duodenal biopsies in pediatric patients undergoing upper intestinal endoscopy.

Kori M, Gladish V, Ziv-Sokolovskaya N, Huszar M, Beer-Gabel M, Reifen R.

J Clin Gastroenterol. 2003 Jul;37(1):39-41.

PMID:
12811207
47.

Faecal elastase 1 levels in premature and full term infants.

Kori M, Maayan-Metzger A, Shamir R, Sirota L, Dinari G.

Arch Dis Child Fetal Neonatal Ed. 2003 Mar;88(2):F106-8.

48.

Synthesis of novel 4,1-benzoxazepine derivatives as squalene synthase inhibitors and their inhibition of cholesterol synthesis.

Miki T, Kori M, Mabuchi H, Tozawa R, Nishimoto T, Sugiyama Y, Teshima K, Yukimasa H.

J Med Chem. 2002 Sep 26;45(20):4571-80.

PMID:
12238936
49.

Microbial enantioselective ester hydrolysis for the preparation of optically active 4,1-benzoxazepine-3-acetic acid derivatives as squalene synthase inhibitors.

Tarui N, Nakahama K, Nagano Y, Izawa M, Matsumoto K, Kori M, Nagata T, Miki T, Yukimasa H.

Chem Pharm Bull (Tokyo). 2002 Jan;50(1):59-65.

50.

Syntheses of (4,1-benzoxazepine-3-ylidene)acetic acid derivatives and their inhibition of squalene synthase.

Miki T, Kori M, Tozawa R, Nakamura M, Sugiyama Y, Yukimasa H.

Chem Pharm Bull (Tokyo). 2002 Jan;50(1):53-8.

Supplemental Content

Support Center